

CLAIMS

1. An isolated polypeptide comprising at least an immunogenic portion of a breast tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474;

(b) sequences that hybridize to a sequence of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474 under moderately stringent conditions; and

(c) a complement of a sequence of (a) or (b).

2. An isolated polypeptide according to claim 1, wherein the polypeptide comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474 or a complement of any of the foregoing polynucleotide sequences.

3. An isolated polypeptide comprising a sequence recited in any one of SEQ ID NO: 176, 179, 181, 469-473 and 475.

4. An isolated polynucleotide encoding at least 15 contiguous amino acid residues of a breast tumor protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474 or a complement of any of the foregoing sequences.

5. An isolated polynucleotide encoding a breast tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474 or a complement of any of the foregoing sequences.

6. An isolated polynucleotide comprising a sequence recited in any one of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411,

413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474.

7. An isolated polynucleotide comprising a sequence that hybridizes to a sequence recited in any one of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474 under moderately stringent conditions.

8. An isolated polynucleotide complementary to a polynucleotide according to any one of claims 4-7.

9. An expression vector comprising a polynucleotide according to any one of claims claim 4-7.

10. A host cell transformed or transfected with an expression vector according to claim 9.

11. An expression vector comprising a polynucleotide according claim 8.

12. A host cell transformed or transfected with an expression vector according to claim 11.

13. A pharmaceutical composition comprising a polypeptide according to claim 1, in combination with a physiologically acceptable carrier.

14. A vaccine comprising a polypeptide according to claim 1, in combination with an immunostimulant.

15. A vaccine according to claim 14, wherein the immunostimulant is an adjuvant.

16. A vaccine according to claim 14, wherein the immunostimulant induces a predominantly Type I response.

17. A pharmaceutical composition comprising a polynucleotide according to claim 4, in combination with a physiologically acceptable carrier.

18. A vaccine comprising a polynucleotide according to claim 4, in combination with an immunostimulant.

19. A vaccine according to claim 18, wherein the immunostimulant is an adjuvant.

20. A vaccine according to claim 18, wherein the immunostimulant induces a predominantly Type I response.

21. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a breast tumor protein that comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474 or a complement of any of the foregoing polynucleotide sequences.

22. A pharmaceutical composition comprising an antibody or fragment thereof according to claim 18, in combination with a physiologically acceptable carrier.

23. A pharmaceutical composition comprising an antigen-presenting cell that expresses a polypeptide according to claim 1, in combination with a pharmaceutically acceptable carrier or excipient.

24. A pharmaceutical composition according to claim 23, wherein the antigen presenting cell is a dendritic cell or a macrophage.

25. A vaccine comprising an antigen-presenting cell that expresses a polypeptide according to claim 1, in combination with an immunostimulant.

26. A vaccine according to claim 25, wherein the immunostimulant is an adjuvant.

27. A vaccine according to claim 25, wherein the immunostimulant induces a predominantly Type I response.

28. A vaccine according to claim 25, wherein the antigen-presenting cell is a dendritic cell.

29. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a polypeptide according to claim 1, and thereby inhibiting the development of a cancer in the patient.

30. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a polynucleotide according to claim 4, and thereby inhibiting the development of a cancer in the patient.

31. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of an antibody or antigen-binding fragment thereof according to claim 21, and thereby inhibiting the development of a cancer in the patient.

32. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of an antigen-presenting cell that expresses a polypeptide according to claim 1, and thereby inhibiting the development of a cancer in the patient.

33. A method according to claim 32, wherein the antigen-presenting cell is a dendritic cell.

34. A method according to any one of claims 29-32, wherein the cancer is breast cancer .

35. A fusion protein comprising at least one polypeptide according to claim 1.

36. A fusion protein according to claim 35, wherein the fusion protein comprises an expression enhancer that increases expression of the fusion protein in a host cell transfected with a polynucleotide encoding the fusion protein.

37. A fusion protein according to claim 35, wherein the fusion protein comprises a T helper epitope that is not present within the polypeptide of claim 1.

38. A fusion protein according to claim 35, wherein the fusion protein comprises an affinity tag.

39. An isolated polynucleotide encoding a fusion protein according to claim 35.

40. A pharmaceutical composition comprising a fusion protein according to claim 32, in combination with a physiologically acceptable carrier.

41. A vaccine comprising a fusion protein according to claim 35, in combination with an immunostimulant.

42. A vaccine according to claim 41, wherein the immunostimulant is an adjuvant.

43. A vaccine according to claim 41, wherein the immunostimulant induces a predominantly Type I response.

44. A pharmaceutical composition comprising a polynucleotide according to claim 40, in combination with a physiologically acceptable carrier.

45. A vaccine comprising a polynucleotide according to claim 40, in combination with an immunostimulant.

46. A vaccine according to claim 45, wherein the immunostimulant is an adjuvant.

47. A vaccine according to claim 45, wherein the immunostimulant induces a predominantly Type I response.

48. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a pharmaceutical composition according to claim 40 or claim 44.

49. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a vaccine according to claim 41 or claim 45.

50. A method for removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NOS: 1-175, 178, 180, 182-468, 474, 476 and 477; and

(ii) complements of the foregoing polynucleotides;

wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the antigen from the sample.

51. A method according to claim 50, wherein the biological sample is blood or a fraction thereof.

52. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological sample treated according to the method of claim 50.

53. A method for stimulating and/or expanding T cells specific for a breast tumor protein, comprising contacting T cells with one or more of:

- (i) a polypeptide according to claim 1;
- (ii) a polynucleotide encoding such a polypeptide; and/or
- (iii) an antigen presenting cell that expresses such a polypeptide;

under conditions and for a time sufficient to permit the stimulation and or expansion of T cells.

54. An isolated T cell population, comprising T cells prepared according to the method of claim 53.

55. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population according to claim 54.

56. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4⁺ and/or CD8⁺ T cells isolated from a patient with at least one component selected from the group consisting of:

- (i) a polypeptide according to claim 1;
- (ii) a polynucleotide encoding such a polypeptide; or
- (iii) an antigen-presenting cell that expresses such a polypeptide;

such that T cells proliferate; and

(b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient.

57. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4⁺ and/or CD8⁺ T cells isolated from a patient with at least one component selected from the group consisting of:

- (i) a polypeptide according to claim 1;
- (ii) a polynucleotide encoding such a polypeptide; or
- (iii) an antigen-presenting cell that expresses such a polypeptide;

such that T cells proliferate;

- (b) cloning at least one proliferated cell; and
- (c) administering to the patient an effective amount of the cloned T cells, and thereby inhibiting the development of a cancer in the patient.

58. A method for determining the presence or absence of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with a binding agent that binds to a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

- (i) polynucleotides recited in any one of SEQ ID NOS: 1-175, 178, 180, 182-468, 474, 476 and 477; and

- (ii) complements of the foregoing polynucleotides;

(b) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(c) comparing the amount of polypeptide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

59. A method according to claim 58, wherein the binding agent is an antibody.

60. A method according to claim 59, wherein the antibody is a monoclonal antibody.

61. A method according to claim 58, wherein the cancer is breast cancer.

62. A method for monitoring the progression of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOS: 1-175, 178, 180, 182-468, 474, 476 and 477 or a complement of any of the foregoing polynucleotides;

(b) detecting in the sample an amount of polypeptide that binds to the binding agent;

(c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and

(d) comparing the amount of polypeptide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

63. A method according to claim 62, wherein the binding agent is an antibody.

64. A method according to claim 63, wherein the antibody is a monoclonal antibody.

65. A method according to claim 62, wherein the cancer is a breast cancer.

66. A method for determining the presence or absence of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOS: 1-175, 178, 180, 182-468, 474, 476 and 477 or a complement of any of the foregoing polynucleotides;

(b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and

(c) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

67. A method according to claim 66, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.

68. A method according to claim 66, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

69. A method for monitoring the progression of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOS: 1-175, 178, 180, 182-468, 474, 476 and 477 or a complement of any of the foregoing polynucleotides;

(b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide;

(c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and

(d) comparing the amount of polynucleotide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

70. A method according to claim 69, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.

71. A method according to claim 69, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

72. A diagnostic kit, comprising:

(a) one or more antibodies according to claim 21; and

(b) a detection reagent comprising a reporter group.

73. A kit according to claim 72, wherein the antibodies are immobilized on a solid support.

74. A kit according to claim 73, wherein the solid support comprises nitrocellulose, latex or a plastic material.

75. A kit according to claim 72, wherein the detection reagent comprises an anti-immunoglobulin, protein G, protein A or lectin.

76. A kit according to claim 72, wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

77. An oligonucleotide comprising 10 to 40 contiguous nucleotides that hybridize under moderately stringent conditions to a polynucleotide that encodes a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474 or a complement of any of the foregoing polynucleotides.

78. A oligonucleotide according to claim 77, wherein the oligonucleotide comprises 10-40 contiguous nucleotides recited in any one of SEQ ID NOS: 2, 4-15, 18-33, 35-47, 49-56, 58, 59, 63-73, 88-116, 141-159, 175, 178, 180, 185, 186, 194, 199, 205, 208, 211, 214-216, 219, 222, 226, 232, 236, 240, 241, 245, 246, 252-268, 320-324, 342, 353, 366-368, 377, 382, 385, 389, 395, 397, 400, 408, 411, 413, 414, 416, 417, 419-423, 426, 427, 429, 431, 435-438, 441, 443-446, 450, 453, 454, 463-468 and 474.

79. A diagnostic kit, comprising:

- (a) an oligonucleotide according to claim 77; and
- (b) a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.